<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328158</url>
  </required_header>
  <id_info>
    <org_study_id>P12-760</org_study_id>
    <nct_id>NCT01328158</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection</brief_title>
  <official_title>Drug Use Investigation of Kaletra Tablets (Quaque Die, QD) on Patients With HIV-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      This study of Kaletra (Lopinavir (LPV)/Ritonavir (RTV)) tablets will be conducted to clarify
      the following with regard to treatment with this drug:

        1. Incidence and conditions of occurrence of adverse reactions in the clinical setting

        2. Factors that may affect the safety and effectiveness of Kaletra (QD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Drug Reactions</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Drug Reactions</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Pregnancy</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Age</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Inpatient/Outpatient</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Previous Treatment of Human Immunodeficiency Virus (HIV)-Infection</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Races</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Route of Infection</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Disease Duration</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Past Medical History</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Allergy</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Diseases</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Renal Disorder</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Liver Disorder</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia With/Without Hepatitis C</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Center for Disease Control (CDC) Classification Category of Severity Before Treatment</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Administration Method of Lopinavir/Ritonavir</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Mean Daily Dose of Lopinavir/Ritonavir</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Use Duration of Lopinavir/Ritonavir</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Drugs</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Non-Drug Treatments</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Types of Concomitant Anti-HIV Drugs</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;. Abbreviations for the following terminologies are used to represent results in below table: NRTIs: Nucleoside Reverse Transcriptase Inhibitors, NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Drugs Other Than Anti-HIV Drugs</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as &quot;Related&quot;, &quot;Relationship cannot be ruled out&quot;, and &quot;Unknown&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>A serious adverse event is an adverse event that 1. requires in patient hospitalization or prolongation of existing hospitalization, 2. results in persistent or significant disability/incapacity, 3. is life-threatening, 4. results in death, 5. is a congenital anomaly/birth defect, or 6. is an important medical event other than the above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cluster of Differentiation 4 (CD4) Cell Count in Treatment-Naive Participants at Each Time Point of Observation</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CD4 Cell Count in Treatment-Experienced Participants at Each Time Point of Observation</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HIV Ribonucleic Acid (RNA) Amount in Treatment-Naive Participants at Each Time Point of Observation</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
    <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HIV RNA Amount in Treatment-Experienced Participants at Each Time Point of Observation</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
    <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each CDC Classification Category of HIV-infection Over Time</measure>
    <time_frame>Up to Month 60 after first dose of Lopinavir/Ritonavir</time_frame>
    <description>CDC Categories include Category A: asymptomatic acute phase, Category B: symptomatic other than A or C, and Category C: having an AIDS-indicator disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Naive Participants</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
    <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Experienced Participants</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
    <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">236</enrollment>
  <condition>Human Immunodeficiency Virus Infection</condition>
  <arm_group>
    <arm_group_label>Lopinavir/Ritonavir</arm_group_label>
    <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All participants who receive Kaletra for the treatment of Human Immunodeficiency Virus
        infection per approved label
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Participants who were receiving Kaletra or who started Kaletra therapy during the
        registration period.

        Exclusion Criteria:

          -  Participants with a history of hypersensitivity to any ingredient of this drug.

          -  Participants who are undergoing treatment with any of the following drugs: pimozide,
             ergotamine tartrate, dihydroergotamine mesilate, ergometrine maleate,
             methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate,
             sildenafil citrate (Revatio), tadalafil (Adcirca), blonanserin, azelnidipine,
             rivaroxaban, voriconazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susumu Adachi, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie G.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57629</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57630</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57631</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57628</name>
      <address>
        <city>Kitakyushu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57638</name>
      <address>
        <city>Kurashiki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57634</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57625</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57626</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57637</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57632</name>
      <address>
        <city>Nishinomiya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57639</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57640</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57636</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48722</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57641</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57643</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57644</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57645</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57646</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57647</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57648</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57650</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57633</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kaletra, Lopinavir (LPV)/Ritonavir (RTV), Human Immunodeficiency Virus (HIV) infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Survey forms were collected from 236 patients. 16 participants completed treatment with Lopinavir/Ritonavir tablets before the start of enrollment in this study and were excluded from the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lopinavir/Ritonavir</title>
          <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
      <group_list>
        <group group_id="B1">
          <title>Lopinavir/Ritonavir</title>
          <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence/Absence of Previous Treatment of HIV-Infection</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Drug Reactions</title>
        <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Drug Reactions</title>
          <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Drug Reactions</title>
        <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period..</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Drug Reactions</title>
          <description>Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period..</population>
          <units>number of adverse drug reaction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Pregnancy</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All female participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Pregnancy</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All female participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absence of pregnancy (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of pregnancy (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Age</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Age</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 14 Years (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Years to ≤ 29 Years (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Years to ≤ 49 Years (n=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 years to ≤ 64 Years (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 Years (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Inpatient/Outpatient</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Inpatient/Outpatient</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inpatient (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient (n=191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switching between Inpatient and Outpatient (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Previous Treatment of Human Immunodeficiency Virus (HIV)-Infection</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Previous Treatment of Human Immunodeficiency Virus (HIV)-Infection</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Races</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Races</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Japanese (n=204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Route of Infection</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Route of Infection</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Product (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mother-to-Child Transmission (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Accident (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (n=179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Disease Duration</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Disease Duration</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 1 Year (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year to ≤ 2 Years (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years to ≤ 3 Years (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years to ≤ 4 Years (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years to ≤ 5 Years (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5 Years (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Past Medical History</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Past Medical History</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Allergy</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Allergy</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Diseases</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Diseases</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Renal Disorder</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Renal Disorder</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Liver Disorder</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Liver Disorder</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis Present (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilia A: Present (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilia B: Present (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia With/Without Hepatitis C</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia With/Without Hepatitis C</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Hepatitis C (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Hepatitis C (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Center for Disease Control (CDC) Classification Category of Severity Before Treatment</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Center for Disease Control (CDC) Classification Category of Severity Before Treatment</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P-0 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P-1 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P-2 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Administration Method of Lopinavir/Ritonavir</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Administration Method of Lopinavir/Ritonavir</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Tabs × 2 Times/Day (n=156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Tabs × 1 Time/Day (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 × 2 Changing to 4 x 1 Tabs x Times/Day (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switch Between 2x2 and 4x1 Tabs x Times/Day (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (3 Tabs x 2 Times as Other Daily Dose) (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Mean Daily Dose of Lopinavir/Ritonavir</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Mean Daily Dose of Lopinavir/Ritonavir</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Lopinavir 800/Ritonavir 200 mg (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lopinavir 800/Ritonavir 200 mg (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; Lopinavir 800/Ritonavir 200 mg (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Use Duration of Lopinavir/Ritonavir</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Use Duration of Lopinavir/Ritonavir</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 30 Days (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 Days to ≤ 180 Days (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181 Days to ≤ 364 Days (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 365 Days (n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Undescribed (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Drugs</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Drugs</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Non-Drug Treatments</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Non-Drug Treatments</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Types of Concomitant Anti-HIV Drugs</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”. Abbreviations for the following terminologies are used to represent results in below table: NRTIs: Nucleoside Reverse Transcriptase Inhibitors, NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Types of Concomitant Anti-HIV Drugs</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”. Abbreviations for the following terminologies are used to represent results in below table: NRTIs: Nucleoside Reverse Transcriptase Inhibitors, NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRTIs (n=214</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTIs (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Integrase Inhibitors (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCR5 Inhibitors (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Drugs Other Than Anti-HIV Drugs</title>
        <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Drugs Other Than Anti-HIV Drugs</title>
          <description>Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as “Related”, “Relationship cannot be ruled out”, and “Unknown”.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>A serious adverse event is an adverse event that 1. requires in patient hospitalization or prolongation of existing hospitalization, 2. results in persistent or significant disability/incapacity, 3. is life-threatening, 4. results in death, 5. is a congenital anomaly/birth defect, or 6. is an important medical event other than the above.</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>A serious adverse event is an adverse event that 1. requires in patient hospitalization or prolongation of existing hospitalization, 2. results in persistent or significant disability/incapacity, 3. is life-threatening, 4. results in death, 5. is a congenital anomaly/birth defect, or 6. is an important medical event other than the above.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cluster of Differentiation 4 (CD4) Cell Count in Treatment-Naive Participants at Each Time Point of Observation</title>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cluster of Differentiation 4 (CD4) Cell Count in Treatment-Naive Participants at Each Time Point of Observation</title>
          <population>Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use Duration: 0 Months (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.5" spread="130.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 3 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 9 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 12 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 24 Months (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.3" spread="225.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 36 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.0" spread="200.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 48 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 60 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean CD4 Cell Count in Treatment-Experienced Participants at Each Time Point of Observation</title>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean CD4 Cell Count in Treatment-Experienced Participants at Each Time Point of Observation</title>
          <population>Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use Duration: 0 Months (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654.5" spread="280.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 3 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="835.0">Standard Deviation cannot be calculated as CD4 cell count is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 9 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713.5" spread="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 12 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="878.5" spread="229.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 24 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 36 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 48 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 60 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean HIV Ribonucleic Acid (RNA) Amount in Treatment-Naive Participants at Each Time Point of Observation</title>
        <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean HIV Ribonucleic Acid (RNA) Amount in Treatment-Naive Participants at Each Time Point of Observation</title>
          <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
          <population>Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set.</population>
          <units>Log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use Duration: 0 Months (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 3 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 9 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 12 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 24 Months (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 36 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 48 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 60 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean HIV RNA Amount in Treatment-Experienced Participants at Each Time Point of Observation</title>
        <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean HIV RNA Amount in Treatment-Experienced Participants at Each Time Point of Observation</title>
          <description>For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
          <population>Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set.</population>
          <units>Log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use Duration: 0 Months (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 3 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6">Standard Deviation cannot be calculated as HIV-RNA value is available for 1 subject only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 9 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 12 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 24 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 36 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 48 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use Duration: 60 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each CDC Classification Category of HIV-infection Over Time</title>
        <description>CDC Categories include Category A: asymptomatic acute phase, Category B: symptomatic other than A or C, and Category C: having an AIDS-indicator disease.</description>
        <time_frame>Up to Month 60 after first dose of Lopinavir/Ritonavir</time_frame>
        <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir: Baseline CDC Category A</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
          <group group_id="O2">
            <title>Lopinavir/Ritonavir: Baseline CDC Category C</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
          <group group_id="O3">
            <title>Lopinavir/Ritonavir: Baseline CDC Category Unknown</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each CDC Classification Category of HIV-infection Over Time</title>
          <description>CDC Categories include Category A: asymptomatic acute phase, Category B: symptomatic other than A or C, and Category C: having an AIDS-indicator disease.</description>
          <population>All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDC Category A After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC Category B After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC Category C After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC Category Unknown After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Naive Participants</title>
        <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Naive Participants</title>
          <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
          <population>Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0 Months (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AT 9 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24 Months (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 36 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 48 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 60 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Experienced Participants</title>
        <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir</time_frame>
        <population>Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lopinavir/Ritonavir</title>
            <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Experienced Participants</title>
          <description>Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as &lt; 400 copies/mL, the result was recorded as 399 copies/mL.</description>
          <population>Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0 Months (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 Months (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 9 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 Months (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 36 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 48 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 60 Months (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No data available for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 60 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lopinavir/Ritonavir</title>
          <description>Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AMOEBIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LYMPH NODE TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM AVIUM COMPLEX INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>ENTERITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HEPATITIS VIRUS-ASSOCIATED NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ANAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>THREATENED LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA V17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>CORNEAL EROSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>CHORIORETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BETA 2 MICROGLOBULIN URINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>GLUCOSE URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LIPIDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LOW DENSITY LIPOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>PROTEIN URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATASAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LIPID METABOLISM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPO HDL CHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GYNAECOMASTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>LIPODYSTROPHY ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AbbVie Japan PMOS Desk</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>+81-3-4577-1125</phone>
      <email>abvj-pmos@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

